CvC-SAD (Clinician vs Coach)Self-help Versions in a RCT
Chinese Internet-delivered Cognitive Therapy for Social Anxiety Disorder in Hong Kong: A Randomised Controlled Noninferiority Trial to Compare Clinician Versus Coach Guidance
1 other identifier
interventional
110
1 country
1
Brief Summary
Background: Social Anxiety Disorder (SAD) is a common mental problem, where people experience severe and disabling anxiety about social situations and interactions. It is highly prevalent world-wide and in Hong Kong, causing significant suffering/distress. While evidence-based interventions exist, e.g., cognitive behavioural therapy (CBT), there will be not enough trained therapists to meet the treatment demand so that the majority of the SAD patients receive no treatment. Internet-based therapies may offer a solution, given that they deliver treatment more cost-efficiently by requiring lesser therapist time so that more patients can be treated with the same therapist resources. One UK internet-based CBT protocol for SAD, iCBT(C\&W), shows high efficacy and efficiency in initial UK and Hong Kong trials with Englishspeaking patients. Objectives:
- 1.To develop and confirm the efficacy of a Chinese-language version of iCBT(C\&W), administered by clinical psychologists in standard therapist-guided format.
- 2.To develop an even more cost-efficient new self-help format with some minimal 'coaching' performed by trained psychology bachelor-level graduates - its efficacy expected as 'noninferior' to that of the therapist-guided format.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2023
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 23, 2022
CompletedFirst Posted
Study publicly available on registry
March 23, 2022
CompletedStudy Start
First participant enrolled
May 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
February 18, 2026
February 1, 2026
3.4 years
February 23, 2022
February 13, 2026
Conditions
Outcome Measures
Primary Outcomes (3)
Liebowitz Social Anxiety Scale, Self-report version (LSAS)
LSAS consists of twenty-four items to assess individual's fear and avoidance towards different social interactions and performance situations. A total of six subscale scores could be obtained in LSAS, including the total fear, fear of social interactions, fear of performance situations, total avoidance, avoidance of social interactions, and avoidance of performance situations.
through study completion, an average of 14 weeks
Liebowitz Social Anxiety Scale, Self-report version (LSAS)
LSAS consists of twenty-four items to assess individual's fear and avoidance towards different social interactions and performance situations. A total of six subscale scores could be obtained in LSAS, including the total fear, fear of social interactions, fear of performance situations, total avoidance, avoidance of social interactions, and avoidance of performance situations.
at 3-month post-treatment follow-up
Liebowitz Social Anxiety Scale, Self-report version (LSAS)
LSAS consists of twenty-four items to assess individual's fear and avoidance towards different social interactions and performance situations. A total of six subscale scores could be obtained in LSAS, including the total fear, fear of social interactions, fear of performance situations, total avoidance, avoidance of social interactions, and avoidance of performance situations.
at 9-month post-treatment follow-up
Secondary Outcomes (22)
Patient Health Questionnaire-Depression Scale (PHQ-9)
through study completion, an average of 14 weeks
Patient Health Questionnaire-Depression Scale (PHQ-9)
at 3-month post-treatment follow-up
Patient Health Questionnaire-Depression Scale (PHQ-9)
at 9-month post-treatment follow-up
Generalized Anxiety Disorder-7 (GAD-7)
through study completion, an average of 14 weeks
Generalized Anxiety Disorder-7 (GAD-7)
at 3-month post-treatment follow-up
- +17 more secondary outcomes
Study Arms (3)
Standard therapist-guided iCT-SAD vs. Waitlist
EXPERIMENTALto examine if standard iCT-SAD delivered in Chinese is superior to waitlist. participants in the experimental group would receive iCBT(C\&W) for SAD under the guidance of trained therapist.
Guided self-help iCT-SAD vs. Waitlist
EXPERIMENTALto examine if guided self-help iCT-SAD delivered in Chinese is superior to waitlist. participants in the experimental group would receive iCBT(C\&W) for SAD under the guidance of trained coaches.
Standard therapist-guided iCT-SAD vs. Guided self-help iCT-SAD
EXPERIMENTALto examine if guided self-help iCT-SAD is noninferior to standard iCT-SAD. participants would be randomised into two groups. one group of participants would receive iCBT(C\&W) for SAD under the guidance of trained therapist while the other group of participants would receive iCBT(C\&W) for SAD under the guidance of trained coaches.
Interventions
iCBT(C\&W) for SAD implements all the key procedures of the face-to-face treatment. Patients are guided through the treatment by using secure messaging and regular telephone or webcam calls. The treatment comprises a series of online modules, each of which includes educational texts, patient testimonies, video illustrations, case examples, questionand- answer boxes, monitoring sheets, behavioural experiments and other homework assignments.
Eligibility Criteria
You may qualify if:
- Meets DSM-5 criteria for SAD (SAD must be generalised, not the 'performance only' subtype)
- Considers SAD their main problem
- Age 18 or over (no upper age limit)
- No current psychotropic mediation, or on a stable dose for at least two months without improvement, and willing to remain at this dose throughout trial
- Participant agrees not to start any other forms of treatment during the trial
- Chinese resident of Hong Kong
- Proficient in written traditional Chinese and spoken Cantonese
- Internet access from home
You may not qualify if:
- current or past psychosis, bipolar disorder, or borderline personality disorder
- active suicidality
- 'Moderate' or 'Severe' Alcohol Use Disorder or Substance Use Disorder (based on DSM-5)
- No current or previous CBT for SAD (defined as at least 5 sessions, and including an exposure component), including internet-CBT studies
- Not another current emotional problem that is the participant's main concern (Participant must not be largely absorbed in another emotional problem, for which it would be unethical not to address as a priority)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Chinese University of Hong Kong
Shatin, Hong Kong
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Patrick Leung, Prof.
Chinese University of Hong Kong
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
February 23, 2022
First Posted
March 23, 2022
Study Start
May 1, 2023
Primary Completion (Estimated)
September 30, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
February 18, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share